Company / Working Capital
TG Therapeutics, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$477.0M
FY2025
5-year range
$115.1M / $477.0M
FY2021-FY2025
Trend
+0.3%
vs FY2024
Sector context
#98 of 213
Health Care
What the data says
At $477M, TG Therapeutics, Inc.'s working capital ranks #98 of 213 in the Health Care sector. Working Capital has increased for 3 consecutive years, from $115M in FY2022 to $477M in FY2025.
Based on SEC 10-K filings.
$477M in FY2025 with a 5-year CAGR of -1.9%.
Improved from $264M to $477M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +60.6%
- 5-Year CAGR
- -1.9%
- 10-Year CAGR
- -
Sector benchmark
#98 of 213 in Health CareTop 46% of 213This company $477.0M Sector average $934.6M
▼
-49.0% below sector average
Key checks
Key Insights
- TG Therapeutics, Inc.'s working capital has grown for 3 consecutive years.
- 5-year CAGR of -1.9%, indicating a declining trend.
- In FY2025, working capital increased 0.3% year-over-year.
- Ranks #98 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $477.0M | +0.3% |
| FY2024 | $475.7M | +80.0% |
| FY2023 | $264.2M | +129.6% |
| FY2022 | $115.1M | -56.7% |
| FY2021 | $265.6M | -49.3% |
| FY2020 | $524.2M | +710.2% |
| FY2019 | $64.7M | +61.0% |
| FY2018 | $40.2M | -38.5% |
| FY2017 | $65.4M | +92.3% |
| FY2016 | $34.0M | -55.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026